CRMAX
Price
$12.86
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
VSEMX
Price
$241.18
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
Ad is loading...

CRMAX vs VSEMX

Header iconCRMAX vs VSEMX Comparison
Open Charts CRMAX vs VSEMXBanner chart's image
CRM Small/Mid Cap Value I
Price$12.86
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Extended Market Index Instl Sel
Price$241.18
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
CRMAX vs VSEMX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CRMAX vs. VSEMX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRMAX is a StrongBuy and VSEMX is a Buy.

FUNDAMENTALS
Fundamentals
VSEMX has more cash in the bank: 107B vs. CRMAX (187M). VSEMX pays higher dividends than CRMAX: VSEMX (1.23) vs CRMAX (0.59). CRMAX was incepted earlier than VSEMX: CRMAX (20 years) vs VSEMX (8 years). CRMAX is a more actively managed with annual turnover of: 42.00 vs. VSEMX (11.00). CRMAX has a lower initial minimum investment than VSEMX: CRMAX (2500) vs VSEMX (3000000000). VSEMX (36.21) and CRMAX (35.01) have marching annual gain over last year. VSEMX return over 5 years is better than : 65.07 vs. CRMAX (13.84).
CRMAXVSEMXCRMAX / VSEMX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence20 years8 years-
Gain YTD21.09220.635102%
Front LoadN/AN/A-
Min. Initial Investment250030000000000%
Min. Initial Investment IRAN/AN/A-
Net Assets187M107B0%
Annual Yield % from dividends0.591.2348%
Returns for 1 year35.0136.2197%
Returns for 3 years-18.340.49-3,741%
Returns for 5 years13.8465.0721%
Returns for 10 years-26.26N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNTS0.670.06
+9.30%
Momentus
HPP4.210.17
+4.21%
Hudson Pacific Properties
K81.180.15
+0.19%
Kellanova
WDFC285.73-4.39
-1.51%
WD-40 Company
NVCT10.67-0.31
-2.82%
Nuvectis Pharma